ContraFect: Rises on breakthrough status for antibacterial

CONTRAFECT

24/02/2020 15:40

** Drug developer's shares  CFRX.O  rise 3.5% to $11.4
    ** U.S. FDA grants breakthrough therapy designation to
CFRX's experimental antibacterial, exebacase, for certain blood
infections when used along with standard antibiotics in adults
 urn:newsml:reuters.com:*:nGNX9mWVlz
    ** Designation expedites the development and review of
medicines for serious or life-threatening diseases
    ** CFRX says a single late-stage study, in addition to data
so far, may serve as the basis for FDA marketing application and
potential approval of drug 
    ** Up to Friday's close, CFRX surged ~77% YTD

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))